Mayne Pharma Group (MAYNF)
OTHER OTC:MAYNF
Want to see MAYNF full AI Analyst Report?
MAYNF Stock Chart & Stats
$3.82
-$0.09(-2.96%)
At close: 4:00 PM EST
$3.82
-$0.09(-2.96%)
Day’s Range― - ―
52-Week Range$1.44 - $4.59
Previous CloseN/A
Volume375.00
Average Volume (3M)2.61K
Market Cap
$152.03M
Enterprise Value$186.89M
Total Cash (Recent Filing)$67.35M
Total Debt (Recent Filing)$44.62M
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Aug 20, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.07
Shares Outstanding81,245,830
10 Day Avg. Volume15
30 Day Avg. Volume2,610
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.11
Price to Sales (P/S)1.01
P/FCF Ratio79.25
Enterprise Value/Market Cap1.23
Enterprise Value/Revenue0.46
Enterprise Value/Gross Profit0.84
Enterprise Value/Ebitda7.99
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Gross Margin ImprovementAn almost 4ppt gross margin uplift alongside stable revenue signals a durable shift to higher‑quality sales mix and tighter margin control. Sustained higher gross margins support margin recovery, improve cash conversion potential and provide room to invest in growth or absorb costs.
Dermatology Margin TurnaroundA material margin and direct contribution lift in Dermatology reflects successful branded mix and pricing execution. This structural move from lower‑margin volumes toward branded dermatology enhances recurring cash generation and strengthens a higher‑margin growth pillar.
Cash Generation & LiquidityPositive adjusted operating cash flow combined with a sizable cash buffer provides durable liquidity to fund marketing, the Salisbury upgrade and selective investments. This cash position and operating cash generation enhance financial flexibility over the medium term.
Bears Say
Negative Profitability & ROEA deeply negative ROE and reported net losses indicate persistent inability to turn equity into returns. Structural unprofitability constrains reinvestment, limits shareholder value creation and means sustained operational improvements are required before equity holders see durable recovery.
Poor Cash ConversionSevere FCF deterioration and very low cash conversion from earnings weaken the firm's capacity to self‑fund growth or absorb shocks. Over the medium term this increases reliance on cash reserves, restricts M&A/buyback optionality and heightens vulnerability to unexpected cash demands.
Earn‑outs, Litigation & Other ContingenciesLarge earn‑out adjustments and significant diligence, litigation and transaction charges create recurring cash and execution risk. These contingent obligations and ongoing legal proceedings can divert capital, increase expense volatility and reduce management's ability to focus on operational growth.
Mayne Pharma Group News
MAYNF FAQ
What was Mayne Pharma Group’s price range in the past 12 months?
Mayne Pharma Group lowest stock price was $1.44 and its highest was $4.59 in the past 12 months.
What is Mayne Pharma Group’s market cap?
Mayne Pharma Group’s market cap is $152.03M.
When is Mayne Pharma Group’s upcoming earnings report date?
Mayne Pharma Group’s upcoming earnings report date is Aug 20, 2026 which is in 102 days.
How were Mayne Pharma Group’s earnings last quarter?
Mayne Pharma Group released its earnings results on Feb 22, 2026. The company reported -$0.107 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.107.
Is Mayne Pharma Group overvalued?
According to Wall Street analysts Mayne Pharma Group’s price is currently Overvalued.
Does Mayne Pharma Group pay dividends?
Mayne Pharma Group pays a Notavailable dividend of $0.378 which represents an annual dividend yield of N/A. See more information on Mayne Pharma Group dividends here
What is Mayne Pharma Group’s EPS estimate?
Mayne Pharma Group’s EPS estimate is -0.22.
How many shares outstanding does Mayne Pharma Group have?
Mayne Pharma Group has 81,245,830 shares outstanding.
What happened to Mayne Pharma Group’s price movement after its last earnings report?
Mayne Pharma Group reported an EPS of -$0.107 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.424%.
Which hedge fund is a major shareholder of Mayne Pharma Group?
Currently, no hedge funds are holding shares in MAYNF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mayne Pharma Group Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.78%
12-Months-Change
Fundamentals
Return on Equity
-23.02%
Trailing 12-Months
Asset Growth
-10.41%
Trailing 12-Months
Company Description
Mayne Pharma Group
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. The company operates through four segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. It provides oral drug delivery systems; and contract pharmaceutical development, manufacturing, and analytical services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
MAYNF Company Deck
MAYNF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a generally constructive picture: the underlying business remained cash generative with improved gross margins, higher total direct contribution, strong Dermatology profitability and clear momentum across multiple Women's Health products. These positives are tempered by an 8% decline in underlying EBITDA, significant one‑off noncash earn‑out and litigation/transaction charges, elevated near‑term legal and earn‑out cash outflows, ANNOVERA returns issues and an investment phase in International that compressed contribution. Management framed many negatives as discrete or investment‑led and emphasized strategic repositioning, operational improvements and capital allocation optionality.View all MAYNF earnings summariesTechnical Analysis
Starpharma Holdings Limited
―
Vita Life Sciences Limited
―
Medical Developments International Limited
―
Botanix Pharmaceuticals Limited
―
Recce Pharmaceuticals Ltd.
―
Ownership Overview
0.32% Insiders
3.50% Mutual Funds
<0.01% Other Institutional Investors
94.06% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---